Opus Genetics, Inc. (FRA:R3X1)
Germany · Delayed Price · Currency is EUR | Market Cap | 285.47M +454.5% |
| Revenue (ttm) | 10.39M -12.2% |
| Net Income | -92.74M |
| EPS | -1.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 3.200 |
| Previous Close | 3.200 |
| Day's Range | 3.200 - 3.500 |
| 52-Week Range | 0.720 - 4.840 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Opus Genetics
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial numbers in USD Financial StatementsNews
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
Opus Genetics (IRD) announced the company will be added as a member of the broad-market Russell 3000, the Russell 2000 and the Russell Microcap Indexes, effective when the U.S. market…
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target Opus is a gene therapy company focused on inherited retinal disease, notes the analyst,…
Opus Genetics assumed with a Buy at Chardan
Chardan assumed coverage of Opus Genetics (IRD) with a Buy rating and a price target of $13, up from $11. The company’s Virtual R&D Science Forum laid the scientific rationale…
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2...
Opus Genetics Transcript: R&D Day 2026
A robust gene therapy pipeline is advancing for inherited retinal diseases, with multiple programs entering or progressing through clinical trials and early data showing functional improvements. Strategic partnerships, broad patient engagement, and efficient manufacturing support a strong outlook, with several clinical readouts expected by 2027.
Opus Genetics Slides: FY 2026
Opus Genetics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 16, 2026.
Opus Genetics management to meet with BTIG
Biotechnology Analyst Shrader holds a meeting with management in San Francisco on June 23 hosted by BTIG.
Opus Genetics registers to sell 2.68M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 2.68M shares of common stock. The company is not selling any…
Opus Genetics Registration statement: Registration filing
Opus Genetics filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Opus Genetics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Opus Genetics (IRD) with a Buy rating and $16 price target
Opus Genetics management to meet with Citizens
Meeting to be held in Minneapolis on June 11 hosted by Citizens.
Opus Genetics Transcript: Jefferies Global Healthcare Conference 2026
Seven gene therapy programs for inherited retinal diseases are advancing rapidly, with pivotal data for LCA5 and first-in-human data for BEST1 expected soon. Early clinical results show dramatic vision improvements, and a strong financial position supports progress toward multiple approvals.
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Slides: Investor presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on May 30, 2026.
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bli...
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics initiated with an Outperform at Leerink
Leerink initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target Opus is a clinical-stage company developing gene therapies for inherited retinal disorders, the analyst...
Opus Genetics initiated with an Outperform at Leerink
Leerink analyst Lili Nsongo initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target
Opus Genetics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The company is advancing a robust gene therapy pipeline for inherited retinal diseases, with multiple programs entering the clinic and key data readouts expected in 2024. Regulatory designations and a strong cash position support progress toward pivotal trials and potential non-dilutive funding.
Opus Genetics Slides: Corporate presentation
Opus Genetics has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapie...
Opus Genetics price target lowered to $11 from $12 at Citizens
Citizens lowered the firm’s price target on Opus Genetics (IRD) to $11 from $12 and keeps an Outperform rating on the shares. Recent ARVO data continue to support OPGx-LCA5’s durable…
Opus Genetics reports Q1 EPS (75c), consensus (14c)
Reports Q1 revenue $2.16M, consensus $2.93M. “With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics (IRD) is entering a defining stretch where we believe our…
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepte...